Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine group B - GSK

X
Drug Profile

Meningococcal vaccine group B - GSK

Alternative Names: 4CMenB; Bexsero; Four component, meningococcal serogroup B vaccine (4CMenB) - GSK; GSK-3536829; GSK-3536829A; MenB; MenB+OMV NZ - GSK; Meningococcal B recombinant vaccine - GSK; Multi-component meningococcal B vaccine (Bexsero) - GSK; rMenB+OMV NZ

Latest Information Update: 24 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Norwegian Institute of Public Health; Novartis
  • Developer GSK; Novartis
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal group B infections

Most Recent Events

  • 24 May 2024 Phase-III clinical trials in Meningococcal group B infections (In infants, In children, In adolescents, In adults, In the elderly, Prevention) in USA (IM) (GSK Pipeline, May 2024)
  • 13 Sep 2022 GlaxoSmithKline completes its phase III trial for Meningococcal B infections (In adults, In adolescents, In volunteers) in USA, Australia, Finland, Turkey, Canada, Czech Republic and Estonia (NCT04502693)
  • 21 Oct 2020 Pooled analysis for efficacy data from phase II, II/III trials Meningococcal group B infections (In adolescents) released by GlaxoSmithKline
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top